Advanced Search
Contact | Corporate | Help

Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

Sponsors:
  • Massachusetts General Hospital
  • Dana-Farber Cancer Institute
  • Emory University
  • The University of North Carolina, Chapel Hill
  • Genentech
  • OSI Pharmaceuticals
Phases:
  • Phase II
IndicationsAcronym:
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: Bevacizumab
  • Drug: erlotinib
  • Drug: Sulindac
Enrollment:
82

Additional information about NCT00392665.


SourceSolution © 2008-2012